Research letterPatients with hidradenitis suppurativa may suffer from neuropathic pain: A Finnish multicenter study
References (5)
- et al.
Patients with hidradenitis suppurativa have a high psychiatric disease burden: a Finnish nationwide registry study
J Invest Dermatol
(2018) - et al.
Morbidity in patients with hidradenitis suppurativa
Br J Dermatol
(2001)
Cited by (13)
Hidradenitis suppurativa: Basic considerations for its approach: A narrative review
2021, Annals of Medicine and SurgeryCitation Excerpt :Regarding chronic pain, the use of NSAIDs is recommended as a first line and as a second line there are pregabalin, gabapentin, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors [25–31]. The management of the HS will be carried out depending on the Hurley classification (Table 4); Thus, for stage I, topical clindamycin 1% can be used, it has been shown to reduce pustules but has no effect on inflammatory nodules or abscesses [28], so the mainstay is management with systemic antibiotics with tetracyclines, being of choice doxycycline at a dose of 100 mg every 12 h. Topical clindamycin (0.1%) twice daily was found to be as effective as oral tetracyclines (500 mg) for stage I lesions [4]. In the second line for stage I but first line for stage II, rifampicin associated with clindamycin, both at doses of 300 mg twice a day for 10 days, with a response range of 71–85% but with the risk of infection by Clostridium difficile [31–34].
Pain management in hidradenitis suppurativa and a proposed treatment algorithm
2021, Journal of the American Academy of DermatologyWhat's new in clinical dermatology?
2020, Annales de Dermatologie et de VenereologieNew treatments and new assessment instruments for Hidradenitis suppurativa
2022, Experimental Dermatology
Funding sources: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
Conflicts of interest: Dr Huilaja has received educational grants from CSL Behring, Shire, Janssen-Cilag, Novartis, AbbVie, and LEO Pharma; honoraria from Novartis, Sanofi Genzyme, and UCB Pharma for consulting and/or speaking; and is an investigator for AbbVie. Dr Lipitsä has received educational grants from AbbVie and is an investigator for AbbVie. Dr Harvima has received educational grants from AbbVie. Dr Vihervaara has received educational grants from AbbVie, Jansen, Novartis, and Celgene. Dr Pasternack has received educational grants from AbbVie, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi Genzyme; honoraria from AbbVie, Galenica, Eli Lilly, Janssen, Novartis, and Sanofi Genzyme for consulting and/or speaking; participated in clinical studies sponsored by AbbVie, Novartis, Eli Lilly, and Regeneron, and is an investigator for AbbVie. Dr Kouri has received educational grants from Pfizer. Authors Ranta and Hirvonen are employees of AbbVie and may or may not own AbbVie stock. Author Sintonen has no conflicts of interest.
IRB approval status: The Tampere University Hospital Ethics Committee approved this study (R16017/2016).
Reprints not available from the authors.